Thursday, December 2, 2021
News

Results provide evidence for effectiveness: Bharat Biotech on Covaxin study

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | Thursday, 2021 6:15:06 PM IST
The Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday said that the recent study on Covaxin provides 'evidence for effectiveness' of India's first indigenous vaccine against Covid-19.

Reacting to a real-world assessment, which said that Covaxin is 50 per cent effective against symptomatic Covid-19, Bharat Biotech said, "These results provide evidence for effectiveness for Covaxin in real life settings."

The vaccine manufacturer said, "Bharat Biotech commends the investigators from AIIMS on the BBV152 study published in Lancet Infectious Diseases."

The firm further said, "An effectiveness result of 50 per cent achieved during the peak Covid-19 Delta variant wave in India, in a high-risk study population of physicians and healthcare workers, in a health-related environment, and who are challenged repeatedly with high viral loads, provides insights into the efficacy and effectiveness of Covaxin."

In a study published in the journal The Lancet, earlier this month, Bharat Biotech demonstrated Covaxin to be 77.8 per cent effective against Covid-19, and 65.2 per cent against Delta variant.

However, in the latest study researchers at AIIMS acknowledged that the vaccine effectiveness is lower than the efficacy reported by a recently published phase-III randomised control study of BBV152.

Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2 infection, and 1,097 tested negative. The adjusted vaccine effectiveness against symptomatic Covid-19 after two doses of BBV152 with the second dose administered 14 or more days before undergoing RT-PCR testing was 50 per cent.

On the Delta variant, Bharat Biotech noted, "These results compare well with the 65.2 per cent efficacy obtained during the controlled Phase 3 clinical trials of Covaxin conducted among the general population."

Covaxin shot developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV), in July announced the final results of its Phase-III clinical trials.

--IANS avr/dpb

( 321 Words)

2021-11-25-12:12:03 (IANS)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE HEALTH NEWS
Saudi Arabia reports 1st case of Omicron...
Delhi HC pulls up govt, MCDs over failur...
6 people coming from 'at risk' countries...
ICMR approves nine systems for molecular...
NHRC takes cognizance of Muzaffarpur eye...
J&K sees 234 new cases as Covid spread c...
More...
 
INDIA WORLD ASIA
Rajasthan bags investment commitments of...
CBI arrests bank manager, one other in b...
Bihar BJP MLA questions inaction against...
Nearly 1,600 Kisan Rail services operate...
Vice Admiral Biswajit Dasgupta assumes c...
Ban air travel where Omicron is spreadin...
More...    
 
 Top Stories
US court dismisses ex-Yukos shareho... 
Didn't pull the trigger, says actor... 
It's a shame to miss out on T10's f... 
Erdogan replaces Finance Minister a... 
Vice Admiral Biswajit Dasgupta assu... 
Taiwanese legislators call for boyc... 
Nearly 1,600 Kisan Rail services op... 
Hindus, Muslims, Sikhs live harmoni...